Synaptic dysfunction in Parkinson's disease.
Bagetta
Vincenza
V
Laboratorio di Neurofisiologia, Fondazione Santa Lucia, I.R.C.C.S., 00143 Rome, Italy.
Ghiglieri
Veronica
V
Sgobio
Carmelo
C
Calabresi
Paolo
P
Picconi
Barbara
B
D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D001479:Basal Ganglia / Q000473:pathology / Q000502:physiology / Q000503:physiopathology; D002352:Carrier Proteins / Q000378:metabolism / Q000502:physiology; D020820:Dyskinesias / Q000209:etiology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use; D009419:Nerve Tissue Proteins / Q000378:metabolism / Q000502:physiology; D009473:Neuronal Plasticity / Q000502:physiology; D010300:Parkinson Disease / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism / Q000502:physiology; D013569:Synapses / Q000473:pathology / Q000502:physiology*; D009435:Synaptic Transmission / Q000502:physiology
D000978:Antiparkinson Agents; D002352:Carrier Proteins; C485668:GRIN1 protein, human; D009419:Nerve Tissue Proteins; D016194:Receptors, N-Methyl-D-Aspartate; D007980:Levodopa